These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 21334855)

  • 1. Group II metabotropic glutamate receptors and schizophrenia.
    Moreno JL; Sealfon SC; González-Maeso J
    Cell Mol Life Sci; 2009 Dec; 66(23):3777-85. PubMed ID: 19707855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Group II Metabotropic Glutamate Receptors Modulate Sound Evoked and Spontaneous Activity in the Mouse Inferior Colliculus.
    Kristaponyte I; Beebe NL; Young JW; Shanbhag SJ; Schofield BR; Galazyuk AV
    eNeuro; 2021; 8(1):. PubMed ID: 33334826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of Glutamatergic Activity via Bidirectional Activation of Two Select Receptors as a Novel Approach in Antipsychotic Drug Discovery.
    Cieślik P; Wierońska JM
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-Related Declines in Prefrontal Cortical Expression of Metabotropic Glutamate Receptors that Support Working Memory.
    Hernandez CM; McQuail JA; Schwabe MR; Burke SN; Setlow B; Bizon JL
    eNeuro; 2018; 5(3):. PubMed ID: 29971246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developmental expression of mGlu2 and mGlu3 in the mouse brain.
    McOmish CE; Demireva EY; Gingrich JA
    Gene Expr Patterns; 2016 Nov; 22(2):46-53. PubMed ID: 27818290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of mammillary body neurons by direct activation of Group II metabotropic glutamate receptors.
    Lee CC
    Neurotransmitter (Houst); 2016; 3():. PubMed ID: 27390777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs.
    Muguruza C; Meana JJ; Callado LF
    Front Pharmacol; 2016; 7():130. PubMed ID: 27242534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabotropic glutamate receptor 3 (mGlu3; mGluR3; GRM3) in schizophrenia: Antibody characterisation and a semi-quantitative western blot study.
    García-Bea A; Walker MA; Hyde TM; Kleinman JE; Harrison PJ; Lane TA
    Schizophr Res; 2016 Nov; 177(1-3):18-27. PubMed ID: 27130562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings.
    Gogos A; Sbisa AM; Sun J; Gibbons A; Udawela M; Dean B
    Int J Endocrinol; 2015; 2015():615356. PubMed ID: 26491441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment.
    Ellaithy A; Younkin J; González-Maeso J; Logothetis DE
    Trends Neurosci; 2015 Aug; 38(8):506-16. PubMed ID: 26148747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?
    Li ML; Hu XQ; Li F; Gao WJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jul; 60():66-76. PubMed ID: 25724760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of mGluR2 in the developing cerebral cortex of the mouse.
    Venkatadri PS; Lee CC
    J Biomed Sci Eng; 2014 Jul; 7(13):1030-1037. PubMed ID: 25414764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics.
    Matosin N; Fernandez-Enright F; Frank E; Deng C; Wong J; Huang XF; Newell KA
    J Psychiatry Neurosci; 2014 Nov; 39(6):407-16. PubMed ID: 24949866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negativity towards negative results: a discussion of the disconnect between scientific worth and scientific culture.
    Matosin N; Frank E; Engel M; Lum JS; Newell KA
    Dis Model Mech; 2014 Feb; 7(2):171-3. PubMed ID: 24713271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholinergic connectivity: it's implications for psychiatric disorders.
    Scarr E; Gibbons AS; Neo J; Udawela M; Dean B
    Front Cell Neurosci; 2013; 7():55. PubMed ID: 23653591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins.
    de Bartolomeis A; Buonaguro EF; Iasevoli F
    Psychopharmacology (Berl); 2013 Jan; 225(1):1-19. PubMed ID: 23179966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Density of metabotropic glutamate receptors 2 and 3 (mGluR2/3) in the dorsolateral prefrontal cortex does not differ with schizophrenia diagnosis but decreases with age.
    Frank E; Newell KA; Huang XF
    Schizophr Res; 2011 May; 128(1-3):56-60. PubMed ID: 21334855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.
    Engel M; Snikeris P; Matosin N; Newell KA; Huang XF; Frank E
    Psychopharmacology (Berl); 2016 Apr; 233(8):1349-59. PubMed ID: 26861891
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.